Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
NCT07232719Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2025
- Primary completion
- Jul 2027
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of retatrutide in obesity (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change from Baseline in Body Weight at 56 weeks. Started Nov 2025; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07232719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232719.